{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:56:22Z","timestamp":1781636182677,"version":"3.54.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"CCI Holdings Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Vet Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Oral melanoma is one of the most devastating cancers in dogs. We previously developed a novel agent extracted from Japanese butterbur shoots and its petasin derivatives demonstrated anti-proliferative activity in canine oral melanoma cells. The aim of this study was to evaluate the safety and clinical efficacy of the butterbur shoot extract (BSE) in dogs with oral melanoma as a combined phase 1 and 2 study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All enrolled dogs underwent radiation therapy or surgery as local therapy before BSE administration. We enrolled nine dogs in the phase 1 study, and BSE was orally administered at doses escalating from 50 to 200\u00a0mg\/kg. Grade 1 alanine aminotransferase elevation and diarrhoea were observed in each dog. We determined that 200\u00a0mg\/kg BSE was safe to administer. We subsequently administered it to sixteen dogs with stage 3 oral melanoma in the phase 2 study. Their progression-free survival and overall survival were compared with those of the historical controls, and adverse events were assessed. BSE administration significantly extended overall survival but did not prolong progression-free survival. No dose-limiting toxicities were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These results indicate that 200\u00a0mg\/kg of BSE is safe to administer and may improve the outcome of canine oral melanoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12917-026-05326-w","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T07:38:44Z","timestamp":1771573124000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical impact of butterbur shoot extract in dogs with oral melanoma: a combined phase 1 and 2 clinical trial"],"prefix":"10.1186","volume":"22","author":[{"given":"Shunsuke","family":"Noguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Furuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Akao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"key":"5326_CR1","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/B978-0-323-59496-7.00020-7","volume-title":"Withrow & macewen\u2019s small animal clinical oncology","author":"PJ Bergman","year":"2020","unstructured":"Bergman PJ, Selmic LE, Kent MS. Melanoma. In: Vaill DM, Thamm DH, Liptak JM, editors. Withrow & macewen\u2019s small animal clinical oncology. 6th ed. St Louis: Elsevier; 2020. pp. 367\u201381.","edition":"6"},{"key":"5326_CR2","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.2460\/javma.245.11.1266","volume":"245","author":"JL Tuohy","year":"2014","unstructured":"Tuohy JL, Selmic LE, Worley DR, Ehrhart NP, Withrow SJ. Outcome following curative-intent surgery for oral melanoma in dogs: 70 cases (1998\u20132011). J Am Vet Med Assoc. 2014;245:1266\u201373.","journal-title":"J Am Vet Med Assoc"},{"key":"5326_CR3","doi-asserted-by":"crossref","unstructured":"Bergman PJ, A. C-PM, McKnight JA, Leibman NF, Craft DM, Leung C, Liao J, Riviere I, Sadelain M, Hohenhaus AE et al. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine : 2006;24:4582\u20134585.","DOI":"10.1016\/j.vaccine.2005.08.027"},{"key":"5326_CR4","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2460\/javma.245.4.401","volume":"245","author":"SE Boston","year":"2014","unstructured":"Boston SE, Lu X, Culp WTN, Montinaro V, Romanelli G, Dudley RM, Liptak JM, Mestrinho LA, Buracco P. Efficacy of systemic adjuvant therapies administered to dogs after excision of oral malignant melanomas: 151 cases (2001\u20132012). J Am Vet Med Assoc. 2014;245:401\u20137.","journal-title":"J Am Vet Med Assoc"},{"key":"5326_CR5","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.2460\/ajvr.72.12.1631","volume":"72","author":"DA Grosenbaugh","year":"2011","unstructured":"Grosenbaugh DA, Leard AT, Bergman PJ, Klein MK, Meleo K, Susaneck S, Hess PR, Jankowski MK, Jones PD, Leibman NF, et al. Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. Am J Vet Res. 2011;72:1631\u20138.","journal-title":"Am J Vet Res"},{"key":"5326_CR6","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.4102\/jsava.v86i1.1246","volume":"86","author":"JL McLean","year":"2015","unstructured":"McLean JL, Lobetti RG. Use of the melanoma vaccine in 38 dogs: the South African experience. J S Afr Vet Assoc. 2015;86:1246.","journal-title":"J S Afr Vet Assoc"},{"key":"5326_CR7","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/vco.12057","volume":"11","author":"JM Ottnod","year":"2013","unstructured":"Ottnod JM, Smedley RC, Walshaw R, Hauptman JG, Kiupel M, Obradovich JE. A retrospective analysis of the efficacy of oncept vaccine for the adjunct treatment of canine oral malignant melanoma. Vet Comp Oncol. 2013;11:219\u201329.","journal-title":"Vet Comp Oncol"},{"key":"5326_CR8","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1292\/jvms.15-0510","volume":"78","author":"E Treggiari","year":"2016","unstructured":"Treggiari E, Grant JP, North SM. A retrospective review of outcome and survival following surgery and adjuvant xenogeneic DNA vaccination in 32 dogs with oral malignant melanoma. J Vet Med Sci. 2016;78:845\u201350.","journal-title":"J Vet Med Sci"},{"key":"5326_CR9","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/vru.12860","volume":"61","author":"M Turek","year":"2020","unstructured":"Turek M, LaDue T, Looper J, Nagata K, Shiomitsu K, Keyerleber M, Buchholz J, Gieger T, Hetzel S. Multimodality treatment including ONCEPT for canine oral melanoma: A retrospective analysis of 131 dogs. Vet Radiol Ultrasound. 2020;61:471\u201380.","journal-title":"Vet Radiol Ultrasound"},{"key":"5326_CR10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/jsap.12613","volume":"58","author":"S Verganti","year":"2017","unstructured":"Verganti S, Berlato D, Blackwood L, Amores-Fuster I, Polton GA, Elders R, Doyle R, Taylor A, Murphy S. Use of oncept melanoma vaccine in 69 canine oral malignant melanomas in the UK. J Small Anim Pract. 2017;58:10\u20136.","journal-title":"J Small Anim Pract"},{"key":"5326_CR11","doi-asserted-by":"crossref","unstructured":"Giuliano A, Pimentel PAB, Horta RS. Checkpoint Inhibitors in Dogs: Are We There Yet? Cancers (Basel). 2024;16:2003.","DOI":"10.3390\/cancers16112003"},{"key":"5326_CR12","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1111\/vco.12829","volume":"20","author":"M Igase","year":"2022","unstructured":"Igase M, Inanaga S, Tani K, Nakaichi M, Sakai Y, Sakurai M, Kato M, Tsukui T, Mizuno T. Long-term survival of dogs with stage 4 oral malignant melanoma treated with anti-canine PD-1 therapeutic antibody: A follow-up case report. Vet Comp Oncol. 2022;20:901\u20135.","journal-title":"Vet Comp Oncol"},{"key":"5326_CR13","doi-asserted-by":"publisher","first-page":"18311","DOI":"10.1038\/s41598-020-75533-4","volume":"10","author":"M Igase","year":"2020","unstructured":"Igase M, Nemoto Y, Itamoto K, Tani K, Nakaichi M, Sakurai M, Sakai Y, Noguchi S, Kato M, Tsukui T, et al. A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs. Sci Rep. 2020;10:18311.","journal-title":"Sci Rep"},{"key":"5326_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41698-021-00147-6","volume":"5","author":"N Maekawa","year":"2021","unstructured":"Maekawa N, Konnai S, Nishimura M, Kagawa Y, Takagi S, Hosoya K, Ohta H, Kim S, Okagawa T, Izumi Y, et al. PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma. NPJ Precis Oncol. 2021;5:10.","journal-title":"NPJ Precis Oncol"},{"key":"5326_CR15","doi-asserted-by":"publisher","first-page":"8951","DOI":"10.1038\/s41598-017-09444-2","volume":"7","author":"N Maekawa","year":"2017","unstructured":"Maekawa N, Konnai S, Takagi S, Kagawa Y, Okagawa T, Nishimori A, Ikebuchi R, Izumi Y, Deguchi T, Nakajima C, et al. A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma. Sci Rep. 2017;7:8951.","journal-title":"Sci Rep"},{"key":"5326_CR16","doi-asserted-by":"publisher","first-page":"115263","DOI":"10.1016\/j.jep.2022.115263","volume":"293","author":"\u0141 Kulinowski","year":"2022","unstructured":"Kulinowski \u0141, Luca SV, Minceva M, Skalicka-Wo\u017aniak K. A review on the ethnobotany, phytochemistry, Pharmacology and toxicology of butterbur species (Petasites L). J Ethnopharmacol. 2022;293:115263.","journal-title":"J Ethnopharmacol"},{"key":"5326_CR17","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ejpain.2007.06.003","volume":"12","author":"R Oelkers-Ax","year":"2008","unstructured":"Oelkers-Ax R, Leins A, Parzer P, Hillecke T, Bolay HV, Fischer J, Bender S, Hermanns U, Resch F. Butterbur root extract and music therapy in the prevention of childhood migraine: an explorative study. Eur J Pain. 2008;12:301\u201313.","journal-title":"Eur J Pain"},{"key":"5326_CR18","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/BF02850143","volume":"23","author":"R K\u00e4ufeler","year":"2006","unstructured":"K\u00e4ufeler R, Polasek W, Brattstr\u00f6m A, Koetter U. Efficacy and safety of butterbur herbal extract Ze 339 in seasonal allergic rhinitis: postmarketing surveillance study. Adv Ther. 2006;23:373\u201384.","journal-title":"Adv Ther"},{"key":"5326_CR19","doi-asserted-by":"publisher","first-page":"108519","DOI":"10.1016\/j.abb.2020.108519","volume":"692","author":"L Guo","year":"2020","unstructured":"Guo L, Kang JS, Kang NJ, Choi YW. S-petasin induces apoptosis and inhibits cell migration through activation of p53 pathway signaling in melanoma B16F10 cells and A375 cells. Arch Biochem Biophys. 2020;692:108519.","journal-title":"Arch Biochem Biophys"},{"key":"5326_CR20","doi-asserted-by":"publisher","first-page":"5664","DOI":"10.1039\/D0FO00594K","volume":"11","author":"L Guo","year":"2020","unstructured":"Guo L, Kang JS, Park YH, Je BI, Lee YJ, Kang NJ, Park SY, Hwang DY, Choi YW. S-petasin inhibits lipid accumulation in oleic acid-induced HepG2 cells through activation of the AMPK signaling pathway. Food Funct. 2020;11:5664\u201373.","journal-title":"Food Funct"},{"key":"5326_CR21","doi-asserted-by":"publisher","first-page":"4396","DOI":"10.1039\/C9FO00549H","volume":"10","author":"L Guo","year":"2019","unstructured":"Guo L, Li K, CZ W, KJ S, SB G, Choi YW. S-Petasin isolated from petasites japonicus exerts anti-adipogenic activity in the 3T3-L1 cell line by inhibiting PPAR-\u03b3 pathway signaling. Food Funct. 2019;10:4396\u2013406.","journal-title":"Food Funct"},{"key":"5326_CR22","first-page":"1071","volume":"132","author":"X Lyu","year":"2019","unstructured":"Lyu X, Song AL, Bai YL, Xu XD, He DQ, Zhang YC. Inhibitory effects of Petasin on human colon carcinoma cells mediated by inactivation of Akt\/mTOR pathway. Clin Med J (Engl). 2019;132:1071\u20138.","journal-title":"Clin Med J (Engl)"},{"key":"5326_CR23","doi-asserted-by":"publisher","first-page":"e139933","DOI":"10.1172\/JCI139933","volume":"131","author":"K Heishima","year":"2021","unstructured":"Heishima K, Sugito N, Soga T, Nishikawa M, Ito Y, Honda R, Kuranaga Y, Sakai H, Ito R, Nakagawa T, et al. Petasin potently inhibits mitochondrial complex I-based metabolism that supports tumor growth and metastasis. J Clin Invest. 2021;131:e139933.","journal-title":"J Clin Invest"},{"key":"5326_CR24","doi-asserted-by":"publisher","first-page":"e3000410","DOI":"10.1371\/journal.pbio.3000410","volume":"18","author":"N Percie Du Sert","year":"2020","unstructured":"Percie Du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, Browne WJ, Clark A, Cuthill IC, Dirnagl U, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. PLoS Biol. 2020;18:e3000410.","journal-title":"PLoS Biol"},{"key":"5326_CR25","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/vco.12677","volume":"19","author":"AK LeBlanc","year":"2021","unstructured":"LeBlanc AK, Atherton M, Bentley RT, Boudreau CE, Burton JH, Curran KM, Dow S, Giuffrida MA, Kellihan HB, Mason NJ, et al. Veterinary cooperative oncology Group-Common terminology criteria for adverse events (VCOG-CTCAE v2) following investigational therapy in dogs and cats. Vet Comp Oncol. 2021;19:311\u201352.","journal-title":"Vet Comp Oncol"},{"key":"5326_CR26","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/vco.12032","volume":"13","author":"SM Nguyen","year":"2015","unstructured":"Nguyen SM, Thamm DH, Vail DM, London CA. Response evaluation criteria for solid tumours in dogs (v1.0): a veterinary cooperative oncology group (VCOG) consensus document. Vet Comp Oncol. 2015;13:176\u201383.","journal-title":"Vet Comp Oncol"},{"key":"5326_CR27","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.2460\/javma.247.10.1146","volume":"247","author":"M Kawabe","year":"2015","unstructured":"Kawabe M, Mori T, Ito Y, Murakami M, Sakai H, Yanai T, Maruo K. Outcomes of dogs undergoing radiotherapy for treatment of oral malignant melanoma: 111 cases (2006\u20132012). J Am Vet Med Assoc. 2015;247:1146\u201353.","journal-title":"J Am Vet Med Assoc"},{"key":"5326_CR28","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1146\/annurev-cellbio-092910-154237","volume":"27","author":"SY Lunt","year":"2011","unstructured":"Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol. 2011;27:441\u201364.","journal-title":"Annu Rev Cell Dev Biol"},{"key":"5326_CR29","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cell.2016.12.039","volume":"168","author":"MG Vander Heiden","year":"2017","unstructured":"Vander Heiden MG, DeBerardinis RJ. Understanding the intersections between metabolism and cancer biology. Cell. 2017;168:657\u201369.","journal-title":"Cell"}],"container-title":["BMC Veterinary Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12917-026-05326-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-026-05326-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-026-05326-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:33:10Z","timestamp":1781634790000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12917-026-05326-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5326"],"URL":"https:\/\/doi.org\/10.1186\/s12917-026-05326-w","relation":{},"ISSN":["1746-6148"],"issn-type":[{"value":"1746-6148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]},"assertion":[{"value":"12 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This clinical study was approved by the Ethics Review Board of our institute (approval number: R2-001). Written owner consent was an enrolment criterion for all dogs in the study group. This clinical trial was designed according to animal research: reporting of in vivo experiments 2.0 guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SN and MF have received research funding from CCI Holdings Inc. KH and RI are the officers and have financial interests with CCI Holdings Inc. Other authors have no conflict of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"191"}}